BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bettinger D, Spode R, Glaser N, Buettner N, Boettler T, Neumann-Haefelin C, Brunner TB, Gkika E, Maruschke L, Thimme R, Schultheiss M. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience. BMC Gastroenterol 2017;17:98. [PMID: 28797231 DOI: 10.1186/s12876-017-0656-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Mao J, Tan Z, Pan X, Meng F. ASPP2 expression predicts the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. Exp Ther Med 2021;21:397. [PMID: 33680119 DOI: 10.3892/etm.2021.9828] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Li Z, Xiao D, Li X, Zhan P, Wang J, Zhang H. Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA. Eur J Gastroenterol Hepatol 2019;31:885-92. [PMID: 30807446 DOI: 10.1097/MEG.0000000000001373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 De Sanctis V, Soliman AT, Daar S, Alansary N, Kattamis A, Skafida M, Galati MC, Christou S, Campisi S, Messina G, Yassin MA, Canatan D, Di Maio S, Al Jaouni S, Raiola G, Karimi M, Kaleva V, Kakkar S, Mariannis D, Kattamis C. A Concise Review on the Frequency, Major Risk Factors and Surveillance of Hepatocellular Carcinoma (HCC) in β-Thalassemias: Past, Present and Future Perspectives and the ICET-A Experience. Mediterr J Hematol Infect Dis 2020;12:e2020006. [PMID: 31934316 DOI: 10.4084/MJHID.2020.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chen J, Chen YJ, Jiang N, Xu JL, Liang ZM, Bai MJ, Xing YF, Liu Z, Wu XY, Li X. Neutrophil-to-Apolipoprotein A1 Ratio Predicted Overall Survival in Hepatocellular Carcinoma Receiving Transarterial Chemoembolization. Oncologist 2021;26:e1434-44. [PMID: 33675070 DOI: 10.1002/onco.13743] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kim J, Sinn DH, Choi MS, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW. Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment? PLoS One 2019;14:e0213547. [PMID: 30845192 DOI: 10.1371/journal.pone.0213547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Patidar Y, Chandel K, Condati NK, Srinivasan SV, Mukund A, Sarin SK. Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma – A Retrospective Study. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.12.009] [Reference Citation Analysis]
7 Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E. Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer 2019;8:281-94. [PMID: 31602371 DOI: 10.1159/000490260] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
8 Chen A, Li S, Yao Z, Hu J, Cao J, Topatana W, Juengpanich S, Yu H, Shen J, Chen M. Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: A meta-analysis. J Gastroenterol Hepatol 2021;36:302-10. [PMID: 32652685 DOI: 10.1111/jgh.15180] [Reference Citation Analysis]
9 Kim HO, Lee BC, Park C, Kim JK, Park WJ, Lee JE, Lim HS, Jeong WG. Occupational dose and associated factors during transarterial chemoembolization of hepatocellular carcinoma using real-time dosimetry: A simple way to reduce radiation exposure. Medicine (Baltimore) 2022;101:e28744. [PMID: 35089250 DOI: 10.1097/MD.0000000000028744] [Reference Citation Analysis]
10 Papaconstantinou D, Hewitt DB, Brown ZJ, Schizas D, Tsilimigras DI, Pawlik TM. Patient stratification in hepatocellular carcinoma: impact on choice of therapy. Expert Rev Anticancer Ther 2022. [PMID: 35157530 DOI: 10.1080/14737140.2022.2041415] [Reference Citation Analysis]
11 Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31:334-351. [PMID: 32067677 DOI: 10.1016/j.annonc.2019.12.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
12 Chen S, Yang Y, Jiao Y, Hou L, Chang H, Liu S, Yan Z, Rajakani K. Efficacy of Drug-Eluting Bead Transarterial Chemoembolization in the Treatment of Colorectal Cancer Liver Metastasis. Journal of Healthcare Engineering 2022;2022:1-5. [DOI: 10.1155/2022/4930047] [Reference Citation Analysis]
13 Han Y, Cao G, Sun B, Wang J, Yan D, Xu H, Shi Q, Liu Z, Zhi W, Xu L, Liu B, Zou Y. Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. BMC Gastroenterol 2021;21:393. [PMID: 34670512 DOI: 10.1186/s12876-021-01967-3] [Reference Citation Analysis]
14 Chu HH, Kim JH, Shim JH, Yoon SM, Kim PH, Alrashidi I. Chemoembolization Plus Radiotherapy Versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis. Cancers (Basel) 2020;12:E1116. [PMID: 32365655 DOI: 10.3390/cancers12051116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
15 Kim GH, Kim JH, Kim PH, Chu HH, Gwon DI, Ko HK. Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. Korean J Radiol 2021;22:1822-33. [PMID: 34431250 DOI: 10.3348/kjr.2021.0229] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Qi F, Zhou A, Yan L, Yuan X, Wang D, Chang R, Zhang Y, Shi F, Han X, Hou J, Wei L, Zhang X. The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma. J Clin Lab Anal 2020;34:e23158. [PMID: 31821607 DOI: 10.1002/jcla.23158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]